InsiderSignal.AI

InsiderSignal.ai

NTRA - Natera, Inc.

Insider Sale by Chapman Steven Leonard (CEO, Pres)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Chapman Steven Leonard, serving as CEO, Pres at Natera, Inc. (NTRA), sold 5,623 shares at $204.13 per share, for a total transaction value of $1,147,838.00. Following this transaction, Chapman Steven Leonard now holds 156,607 shares of NTRA.

This sale represents a 3.00% decrease in Chapman Steven Leonard's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 10, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 11, 2026, 1 day after the trade was made.

Natera, Inc. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Chapman Steven Leonard

Chapman Steven Leonard

CEO, Pres

Steven Leonard Chapman is the Chief Executive Officer of Natera, Inc., a global leader in cell-free DNA and genetic testing focused on oncology, women's health, and organ health[[1]](https://www.insidertrades.com/natera-inc-stock/steven-leonard-chapman/)[[3]](https://investor.natera.com/governance/board-of-directors/person-details/default.aspx?ItemId=0240acf2-edf5-480e-8b4b-ac6decfb4a65). He has served as CEO since January 2019 and also sits on the company's board of directors[[1]](https://www.insidertrades.com/natera-inc-stock/steven-leonard-chapman/)[[3]](https://investor.natera.com/governance/board-of-directors/person-details/default.aspx?ItemId=0240acf2-edf5-480e-8b4b-ac6decfb4a65). Under his leadership, Natera's stock valuation has grown to approximately $10.3 billion, nearly quadrupling from when he assumed the role[[2]](https://alumni.ucla.edu/class-notes/steve-chapman-02/), with the company achieving year-over-year revenue growth exceeding 40% and consistently outperforming earnings expectations[[1]](https://www.insidertrades.com/natera-inc-stock/steven-leonard-chapman/)[[2]](https://alumni.ucla.edu/class-notes/steve-chapman-02/). Chapman joined Natera in 2010 as Vice President of Sales and progressed through multiple leadership roles, including Chief Commercial Officer and Chief Operating Officer, before his appointment as CEO[[1]](https://www.insidertrades.com/natera-inc-stock/steven-leonard-chapman/)[[3]](https://investor.natera.com/governance/board-of-directors/person-details/default.aspx?ItemId=0240acf2-edf5-480e-8b4b-ac6decfb4a65). As COO, he led the company's commercial entry into the non-invasive prenatal testing market, where Natera's Panorama® test became the market leader despite being fourth to market[[1]](https://www.insidertrades.com/natera-inc-stock/steven-leonard-chapman/). During his tenure as CEO, he has been instrumental in expanding the company's technology into new markets, establishing leadership in molecular residual disease testing with Signatera™ and achieving rapid commercial growth for the Prospera™ transplant assessment test[[1]](https://www.insidertrades.com/natera-inc-stock/steven-leonard-chapman/)[[3]](https://investor.natera.com/governance/board-of-directors/person-details/default.aspx?ItemId=0240acf2-edf5-480e-8b4b-ac6decfb4a65). Prior to joining Natera, Chapman worked at Genzyme Genetics, where he delivered record-breaking commercial growth and developed strategies that transformed pregnancy genetic testing[[1]](https://www.insidertrades.com/natera-inc-stock/steven-leonard-chapman/). He began his career as a researcher in the Department of Human Genetics at UCLA, where he earned his B.S. in microbiology, immunology, and molecular genetics, and designed arrays identifying SNPs associated with multiple sclerosis[[3]](https://investor.natera.com/governance/board-of-directors/person-details/default.aspx?ItemId=0240acf2-edf5-480e-8b4b-ac6decfb4a65). In 2024, Chapman was recognized as one of the top healthcare technology CEOs by Healthcare Technology Report and named "BioTechnology Innovator of the Year" by BioTech Breakthrough[[5]](https://investor.natera.com/news/news-details/2025/Natera-CEO-Steve-Chapman-Recognized-as-a-2024-Top-Healthcare-Technology-CEO-and-BioTechnology-Innovator-of-the-Year/default.aspx).

View full insider profile →

Trade Price

$204.13

Quantity

5,623

Total Value

$1,147,838.00

Shares Owned

156,607

Trade Date

Tuesday, March 10, 2026

5 days ago

SEC Filing Date

Wednesday, March 11, 2026

Filed 1 day after trade

HEALTHCAREDIAGNOSTICS & RESEARCH

About Natera, Inc.

Company Overview

No company information available
View news mentioning NTRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4701252

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime